Inivata to present at the Biotech Showcase in San Francisco

2018, News

Company will also participate in “Generation Genome and Industrial Strategy: Leveraging UK Leadership in Genomics” Panel

Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, today announces that Michael Stocum, CEO of Inivata, will present a company update at the Biotech Showcase™ 2018 held in San Francisco 8 – 10 January. The presentation will take place at 11:00 PST on Tuesday, 9 January at the Hilton San Francisco, Union Square.

Michael Stocum will also participate in the Generation Genome and Industrial Strategy: Leveraging UK Leadership in Genomics panelheld in partnership with the UK BioIndustry Association, Genomics England and MedCity. The panel will be held from 14:00 – 14:45 on 8 January at Parc 55, Level 3, Market Street. The panel will bring together representatives from Genomics England, technology partners, SMEs and the venture community to debate the opportunities and challenges that will shape the growth of the UK’s genomics industry and its impact worldwide. Inivata is currently collaborating with Genomics England as part of the 100,000 Genomes Project, to assess the quality of blood plasma samples and explore the potential of liquid biopsy to improve disease management and cancer patient outcomes.


About Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to Follow us on Twitter @Inivata.


Media Contacts

Consilium Strategic Communications

Chris Gardner/Angela Gray/Sarah Wilson

Paul Rabin (US) +44 (0)20 3709 5700, +1 516 503 0271


Karen Chandler-Smith +44 (0)7900 430235


Our Technology

Our Solutions

Latest News

LinkedIn tracking code Twitter tracking code